Jane Street Group LLC Sells 8,198 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Jane Street Group LLC trimmed its position in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 21.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,718 shares of the company’s stock after selling 8,198 shares during the period. Jane Street Group LLC owned about 0.13% of UroGen Pharma worth $390,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Marshall Wace LLP purchased a new position in shares of UroGen Pharma during the second quarter valued at $719,000. Millennium Management LLC raised its stake in UroGen Pharma by 2,672.0% in the 2nd quarter. Millennium Management LLC now owns 1,160,899 shares of the company’s stock worth $19,480,000 after acquiring an additional 1,119,019 shares during the last quarter. Point72 Asset Management L.P. increased its holdings in UroGen Pharma by 120.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company’s stock worth $41,099,000 after buying an additional 1,337,257 shares during the period. Wesbanco Bank Inc. acquired a new stake in UroGen Pharma during the 3rd quarter worth about $945,000. Finally, Vestal Point Capital LP purchased a new stake in UroGen Pharma in the 3rd quarter worth approximately $5,080,000. 91.29% of the stock is owned by institutional investors.

UroGen Pharma Stock Up 0.6 %

URGN stock opened at $11.08 on Wednesday. UroGen Pharma Ltd. has a 52 week low of $10.26 and a 52 week high of $20.70. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The firm has a 50-day simple moving average of $11.68 and a 200-day simple moving average of $13.44. The stock has a market capitalization of $259.87 million, a P/E ratio of -3.52 and a beta of 1.09.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to analyst estimates of $24.22 million. During the same quarter in the previous year, the firm posted ($0.68) earnings per share. Equities analysts forecast that UroGen Pharma Ltd. will post -3.1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

URGN has been the subject of several analyst reports. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a research note on Monday, October 14th. Oppenheimer reissued an “outperform” rating and set a $40.00 target price on shares of UroGen Pharma in a research note on Wednesday, October 16th. HC Wainwright restated a “buy” rating and set a $60.00 target price on shares of UroGen Pharma in a research report on Tuesday, October 15th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Friday, December 6th. Five research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, UroGen Pharma presently has a consensus rating of “Buy” and a consensus target price of $43.70.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.